B is an amino acid sequence of from three amino acids to the full length of apeptide sequence of human or murine PD1 ectodomain fragments selected from BC loop, FG loop, C-C' loop to C' strand, C strand, D strand, C' strand to C'-C'' loop or is absent;

Z is from one to three peptide sequences arranged in any order each being of from three amino acids up to the full length of a peptide sequence of human or murine PD1 ectodomain fragments selected from D strand, FG loop, G strand, C strand and F strand;

and X is lysine.

13. The compound according to claim 12, wherein A and B are independently an amino acid sequence of from three amino acids to the full length of said BC loop.
14. The compound according to claim 13, wherein A and B are independently the full length of said BC loop.
15. The compound according to claim 12, wherein Z is D strand-FG loop-G strand.
16. The compound according to claim 12, wherein R_1, R_2 and R_3 are absent.
17. The compound according to claim 12, wherein R_3 is C16-acyl.
18. The compound according to claim 12, wherein up to three amino acids are D-amino acids.
19. The compound according to claim 12, wherein all amino acids are D-amino acids.
20. The compound according to claim 12, comprising up to three reduced amide bonds (-CH_2NH-).
21. A compound of Formula I or a pharmaceutically acceptable salt thereof as claimed in claim 1, for use as a medicament.
22. A compound of Formula I or a pharmaceutically acceptable salt thereof as claimed in claim 1, for use as a medicament for the treatment of cancer or infectious disease.
23. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 1, and a pharmaceutically acceptable diluent or carrier.
24. ~~A method of~~ Use of a compound according to any one of claims 1 to 20 in the manufacture of a medicament for modulating an immune response mediated by PD-1 signaling pathway in a subject~~, comprising administering to the subject therapeutically effective amount of~~

~~compound according to any of claims 1-20 such that the immune response in the subject is modulated~~.

~~24.~~25. The use of claim 24, wherein the medicament comprises a therapeutically effective amount of the compound.

26. ~~A method of~~ Use of a compound according to any one of claims 1 to 20 in the manufacture of a medicament for inhibiting growth of tumour cells and/or metastasis in a subject~~, comprising administering to the subject a therapeutically effective amount of compound according to any of claims 1-20 capable of inhibiting the programmed cell death 1 (PD1) signaling pathway~~.

~~25.~~27. The use of claim 26, wherein the medicament comprises a therapeutically effective amount of the compound.

~~26.~~28. ~~The method of claim 25~~The use of claim 26 or claim 27, wherein the tumour cells are of a cancer selected from the group consisting of melanoma, renal cancer, prostate cancer, breast cancer, colon cancer and lung cancer.

~~27.~~29. ~~The method of claim 25~~The use of claim 26 or claim 27, wherein the tumour cells are of a cancer selected from the list consisting of bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumours of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumour angiogenesis, spinal axis tumour, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, and combinations of said cancers.

30. ~~A method of~~ Use of a compound according to any one of claims 1 to 20 in the manufacture of a medicament for treating an infectious disease in a subject ~~comprising administering to the subject a therapeutically effective amount of compound according to any of claims 1-20 capable of inhibiting the programmed cell death 1 (PD1) signaling pathway such that the subject is treated for the infectious disease~~.

~~28.~~31. The use of claim 30, wherein the medicament comprises a therapeutically effective amount of the compound.

32. ~~A method of treating bacterial and viral infections in a subject comprising administering to the subject a therapeutically effective amount of compound according to any of claims 1-20 capable of inhibiting the programmed cell death 1 (PD1) signaling pathway such that the subject is treated~~ Use of a compound according to any one of claims 1 to 20 in the manufacture of a medicament for ~~the~~treating bacterial and viral infections in a subject.

~~29.~~33. The use of claim 32, wherein the medicament comprises a therapeutically effective amount of the compound.